

## Mallesh Pandrala

Senior Physical Research Scientist, Rad/Molecular Imaging Program at Stanford

### Publications

---

#### PUBLICATIONS

- **A New Nrf2 Inhibitor Enhances Chemotherapeutic Effects in Glioblastoma Cells Carrying p53 Mutations.** *Cancers*  
Afjei, R., Sadeghipour, N., Kumar, S. U., Pandrala, M., Kumar, V., Malhotra, S. V., Massoud, T. F., Paulmurugan, R.  
2022; 14 (24)
- **Increased macrophage phagocytic activity with TLR9 agonist conjugation of an anti- *Borrelia burgdorferi* monoclonal antibody.** *Clinical immunology (Orlando, Fla.)*  
Jahanbani, S., Hansen, P. S., Blum, L. K., Bastounis, E. E., Ramadoss, N. S., Pandrala, M., Kirschmann, J. M., Blacker, G. S., Love, Z. Z., Weissman, I. L., Nemati, F., Tal, M. C., Robinson, et al  
2022: 109180
- **Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety.** *Journal of medicinal chemistry*  
Pandrala, M., Bruyneel, A. A., Hnatiuk, A. P., Mercola, M., Malhotra, S. V.  
2022
- **Reengineering Ponatinib to Minimize Cardiovascular Toxicity** *CANCER RESEARCH*  
Hnatiuk, A. P., Bruyneel, A. N., Taylor, D., Pandrala, M., Dheeraj, A., Li, W., Serrano, R., Feyen, D. M., Vu, M. M., Amatya, P., Gupta, S., Nakauchi, Y., Morgado, et al  
2022; 82 (15): 2777-2791
- **Reengineering Ponatinib to Minimize Cardiovascular Toxicity.** *Cancer research*  
Hnatiuk, A. P., Bruyneel, A. A., Taylor, D., Pandrala, M., Dheeraj, A., Li, W., Serrano, R., Feyen, D. A., Vu, M. M., Amatya, P., Gupta, S., Nakauchi, Y., Morgado, et al  
2022
- **SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer.** *Cell reports. Medicine*  
Rice, M. A., Kumar, V., Taylor, D., Garcia-Marques, F. J., Hsu, E., Liu, S., Bermudez, A., Kanchustambham, V., Shankar, V., Inde, Z., Alabi, B. R., Muruganatham, A., Shen, et al  
2022; 3 (2): 100502
- **New Selective Inhibitors of ERG Positive Prostate Cancer: ERG-USU-6 Salt Derivatives.** *ACS medicinal chemistry letters*  
Eldhose, B., Pandrala, M., Xavier, C., Mohamed, A. A., Srivastava, S., Sunkara, A. D., Dobi, A., Malhotra, S. V.  
2021; 12 (11): 1703-1709
- **Polypyridyl iridium(III) based catalysts for highly chemoselective hydrogenation of aldehydes** *JOURNAL OF CATALYSIS*  
Pandrala, M., Resendez, A., Malhotra, S. V.  
2019; 378: 283–88
- **Novel CMKLR1 Inhibitors for Application in Demyelinating Disease** *SCIENTIFIC REPORTS*  
Kumar, V., LaJevic, M., Pandrala, M., Jacobo, S. A., Malhotra, S., Zabel, B. A.  
2019; 9
- **Iridium(III) polypyridyl based new catalysts for highly chemoselective hydrogenation of aldehydes**  
Pandrala, M., Resendez, A., Malhotra, S.  
AMER CHEMICAL SOC.2019
- **Quantitative Proteomic Profiling Reveals Key Pathways in the Anticancer Action of Methoxychalcone Derivatives in Triple Negative Breast Cancer** *JOURNAL OF PROTEOME RESEARCH*

Going, C. C., Tailor, D., Kumar, V., Birk, A. M., Pandrala, M., Rice, M. A., Stoyanova, T., Malhotra, S., Pitteri, S. J.  
2018; 17 (10): 3574–85

● **Quantitative Proteomic Profiling Reveals Key Pathways in the Anticancer Action of Methoxychalcone Derivatives in Triple Negative Breast Cancer.** *Journal of proteome research*

Going, C. C., Tailor, D., Kumar, V., Birk, A. M., Pandrala, M., Rice, M. A., Stoyanova, T., Malhotra, S., Pitteri, S. J.  
2018

● **Design of deferasirox peptide-conjugated ligands for a selective delivery of anticancer Ti(IV) compounds**

Fernandez, L., Tinoco, A., Pandrala, M.  
AMER CHEMICAL SOC.2018

● **Novel chalcone derivatives as potential therapeutic agents for triple negative breast cancer**

Kumar, V., Going, C., Tailor, D., Pandrala, M., Birk, A., Pitteri, S., Malhotra, S.  
AMER CHEMICAL SOC.2018

● **Small molecules facilitating DNA repair in breast cancer cells**

Pandrala, M., Hastak, K., Kumar, V., Gardiner, M., Ford, J., Malhotra, S.  
AMER CHEMICAL SOC.2018

● **Inhibiting guanylate binding protein 1 (GBP1) impedes ovarian cancer progression**

Tailor, D., Kumar, V., Pandrala, M., Resendez, A., Malhotra, S. V.  
AMER ASSOC CANCER RESEARCH.2018

● **Studies to understand Ti(IV) speciation and transport in the human body**

Benjamin-Rivera, J., Tinoco, A., Delgado, Y., Pandrala, M., Vazquez, A., Vazquez, A.  
AMER CHEMICAL SOC.2018

● **A ubiquitous metal, difficult to track: towards an understanding of the regulation of titanium(IV) in humans** *METALLOMICS*

Loza-Rosas, S. A., Saxena, M., Delgado, Y., Gaur, K., Pandrala, M., Tinoco, A. D.  
2017; 9 (4): 346–56

● **Differential Anticancer Activities of the Geometric Isomers of Dinuclear Iridium(III) Complexes** *EUROPEAN JOURNAL OF INORGANIC CHEMISTRY*

Pandrala, M., Sundaraneedi, M. K., Ammit, A. J., Woodward, C. E., Wallace, L., Keene, F., Collins, J.  
2015: 5694–5701

● **Chlorido-containing ruthenium(II) and iridium(III) complexes as antimicrobial agents** *DALTON TRANSACTIONS*

Pandrala, M., Li, F., Feterl, M., Mulyana, Y., Warner, J. M., Wallace, L., Keene, F., Collins, J.  
2013; 42 (13): 4686–94

● **Iridium(III) Complexes Containing 1,10-Phenanthroline and Derivatives: Synthetic, Stereochemical, and Structural Studies, and their Antimicrobial Activity** *AUSTRALIAN JOURNAL OF CHEMISTRY*

Pandrala, M., Li, F., Wallace, L., Steel, P. J., Moore, B., Autschbach, J., Collins, J., Keene, F.  
2013; 66 (9): 1065–73